Table 1.

Calcification parameters over two year follow up.

Coronary Calcification	Rivaroxaban group							VKA group							P value
	t0 (n = 92)		t12 (n = 84)		t24 (n = 45)		P value	t0 (n = 87)		t12 (n = 82)		t24 (n = 46)		P value
	Median	Q1; Q3	Median	Q1; Q3	Median	Q1; Q3		Median	Q1; Q3	Median	Q1; Q3	Median	Q1; Q3
Coronary Agatston score	268.0	92.3; 988.4	307.3	89.1; 1200.8	360.7	90.2; 1075.3	0.59	328.1	131.5; 1587.7	353.6	170.5; 1778.4	380.4	136.4; 1546.9	0.71	0.69
Coronary volume score (ml)	247.7	90.4; 873.2	275.4	93.7; 1033.0	295.8	93.0; 995.3	0.66	292.3	127.4; 1322.1	333.6	155.1; 1481.9	335.5	128.7; 1316.9	0.70	0.95
Coronary mass score (mg)	43.7	16.6; 150.0	51.8	17.1; 196.3	58.5	15.9; 172.0	0.53	58.4	23.4; 274.7	62.5	30.1; 305.4	71.1	24.8; 257.3	0.69	0.50
ΔCoronary Agatston score			41.6	7.4; 114.9	77.2	29.9; 187.6	0.02			32.2	7.0; 136.6	104.1	36.1; 266.7	< 0.01
Δ Coronary volume score (ml)			32.7	5.9; 85.3	61.8	22.9; 137.5	0.03			29.8	10.0; 102.1	87.6	30.8; 223.2	< 0.01
Δ Coronary mass score (mg)			5.9	1.3; 19.3	14.9	4.0; 37.2	0.02			6.4	2.1; 21.5	18.1	6.5; 35.5	< 0.01

MGP levels	Rivaroxaban group							VKA group							P value
	t0 (n = 85)		t12 (n = 72)		t24 (n = 45)		P value	t0 (n = 82)		t12 (n = 76)		t24 (n = 46)		P value
	Median	Q1; Q3	Median	Q1; Q3	Median	Q1; Q3		Median	Q1; Q3	Median	Q1; Q3	Median	Q1; Q3
dp-ucMGP	865.40	577.2; 1448.1	749.7	591.5; 1001.6	788.0	655.5; 948.5	0.45	1289.7	1010.7; 1696.4	1415.1	1108.8; 1717.0	1375.0	1152.0; 1933.0	0.25	< 0.001
Δ dp-uc MGP			− 37.9	− 594.3; 151.7	− 95.2	− 554.1; 156.0	0.90			103.7	− 123.6; 347.5	231.3	− 59.7; 388.1	0.29